Key result
Bioresorbable scaffolds show no significant sex-related differences in 1-year major outcomes after ACS.
Why the study?
Women remain more likely than men to have unfavorable outcomes after PCI for ACS, and data evaluating potential sex-related differences with bioresorbable scaffolds are inconsistent and limited.
Do short-term clinical outcomes differ between men and women treated with Absorb or Magmaris bioresorbable scaffolds for acute coronary syndrome?
Cohort (n=353)
No
Do short-term clinical outcomes differ between men and women treated with Absorb or Magmaris bioresorbable scaffolds for acute coronary syndrome?
In routine clinical practice, short-term outcomes after bioresorbable scaffold implantation for ACS were similar between sexes, with the magnesium-based Magmaris scaffold showing a trend toward fewer events in women than the first-generation Absorb scaffold.
Answers are grounded in this paper and cite their sources.
No sex differences in 1-year outcomes after bioresorbable scaffold implantation for ACS; hypothesis-generating and requires randomized confirmation.
BACKGROUND: Despite the developments in percutaneous coronary interventions (PCI), women are still more likely than men to have unfavorable outcomes after PCI performed in Acute Coronary Syndrome (ACS). The mechanisms of this phenomena are not fully understood. Potential benefits of bioresorbable scaffolds (BRS) may be particularly expressed in the female population. Nevertheless, the data available currently are inconsistent and limited. This study evaluated the gender-related differences in the short-term clinical outcomes in ACS patients treated with implantation of two generations of BRS (first generation, Absorb; second generation, Magmaris). METHODS: The study was divided into two arms. To the first one, we qualified 160 patients with ACS treated with PCI who received 210 Absorb scaffolds. The second arm was composed of 193 patients with ACS who underwent PCI with Magmaris implantation. RESULTS: There were no significant sex-related differences in primary endpoints (cardiovascular-death, myocardial infarction, in-stent thrombosis) or principal secondary endpoints (of target-lesion failure, scaffold restenosis, death from any reason, other cardiovascular events) in either generation of BRS in a 1-year follow-up. CONCLUSIONS: Both genders tended to have a similar outcome in routine clinical practice following BRS implantation due to ACS. The magnesium bioresorbable scaffold (Magmaris) early outcome seemed to be more favorable in comparison to the Absorb scaffold.
No takes yet. Share an insight, caveat, or question.
Włodarczak et al. (2021) conducted a cohort in Acute Coronary Syndrome (ACS) (n=353). Female sex vs. Male sex was evaluated on Composite of death from cardiac causes, myocardial infarction, and stent thrombosis at 1 year (Absorb cohort) (p=0.338). In patients with acute coronary syndrome treated with bioresorbable scaffolds, there were no significant sex-related differences in the primary composite endpoint at 1 year, though women receiving Absorb had an 11.63% event rate compared to 6.84% in men.
Synapse has enriched 10 related papers. Consider them for comparative context: